Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $130

Benzinga Newsdesk www.benzinga.com Positive 84.9%

Neg 0% Neu 0% Pos 84.9%

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from $95 to $130.